ClinicalTrials.govpublic full text
TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
hepatocellular carcinoma, adjuvant therapy, hcc, tqb2450, anlotinib, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 875257
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.